Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes.

Kim SH, Abbasi F, Lamendola C, Liu A, Ariel D, Schaaf P, Grove K, Tomasso V, Ochoa H, Liu YV, Chen YD, Reaven G

Diabetes care8 Jul 2013Cited by 82 (Europe PMC)

PMID23835684PMCIDPMC3781545DOI10.2337/dc13-0354PepBankPUB-23835684

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialSafety outcome
In older adults with overweight or obesity and prediabetes, discontinuation was 31% with liraglutide and 18% with placebo, not significantly different.
In plain wordsIn older adults with overweight and prediabetes, similar shares stopped the study on liraglutide (31%) and placebo (18%).
Peptide
Liraglutide
Outcome
No significant changeStudy discontinuation
Study
n = 68
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.8 mg · 14 weeksAs given in this study (human).
Measurements
Discontinuation
31%
liraglutide
Discontinuation
18%
placebo
Source sentences
Summary
Eleven out of 35 individuals (31%) assigned to liraglutide discontinued the study compared with 6 out of 33 (18%) assigned to placebo (P=0.26).
1 context sentence(design, population, supporting numbers)
Summary · context
We randomized 68 older individuals (mean age, 58±8 years) with overweight/obesity and prediabetes to this double-blind study of liraglutide 1.8 mg versus placebo for 14 weeks.
Report a problemFND-2383568401
02HumanRandomized controlled trialEfficacy outcome
In older adults with overweight or obesity and prediabetes who continued treatment, liraglutide produced about twice the weight loss of placebo (6.8 vs 3.3 kg).
In plain wordsIn older adults with overweight and prediabetes who stayed on treatment, liraglutide led to more weight loss than placebo (6.8 vs 3.3 kg).
Peptide
Liraglutide
Outcome
DecreaseWeight loss in participants who continued treatment
Study
n = 51
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg · 14 weeksAs given in this study (human).
Measurements
Weight loss
6.8 kg
liraglutide
Weight loss
3.3 kg
placebo
Source sentences
Summary
Subjects who continued to use liraglutide (n=24) lost twice as much weight as those using placebo (n=27; 6.8 vs. 3.3 kg; P<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We randomized 68 older individuals (mean age, 58±8 years) with overweight/obesity and prediabetes to this double-blind study of liraglutide 1.8 mg versus placebo for 14 weeks.
Report a problemFND-2383568402
03HumanRandomized controlled trialEfficacy outcome
In older adults with overweight or obesity and prediabetes, liraglutide improved insulin resistance (SSPG -3.2 vs 0.2 mmol/L) compared with placebo.
In plain wordsIn older adults with overweight and prediabetes, liraglutide improved insulin resistance more than placebo.
Peptide
Liraglutide
Outcome
DecreaseInsulin resistance (SSPG concentration)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · 14 weeksAs given in this study (human).
Measurements
SSPG change
−3.2 mmol/L
liraglutide
SSPG change
0.2 mmol/L
placebo
Source sentences
Summary
Liraglutide-treated subjects also had a significant improvement in SSPG concentration (-3.2 vs. 0.2 mmol/L; P<0.001) and significantly (P≤0.04) greater lowering of systolic blood pressure (-8.1 vs. -2.6 mmHg), fasting glucose (-0.5 vs. 0 mmol/L), and triglyceride (-0.4 vs. -0.1 mmol/L) concentration.
1 context sentence(design, population, supporting numbers)
Summary · context
We randomized 68 older individuals (mean age, 58±8 years) with overweight/obesity and prediabetes to this double-blind study of liraglutide 1.8 mg versus placebo for 14 weeks.
Report a problemFND-2383568403
04HumanRandomized controlled trialEfficacy outcome
In older adults with overweight or obesity and prediabetes, liraglutide lowered systolic blood pressure more than placebo (-8.1 vs -2.6 mmHg).
In plain wordsIn older adults with overweight and prediabetes, liraglutide lowered systolic blood pressure more than placebo.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
1.8 mg · 14 weeksAs given in this study (human).
Measurements
Systolic BP change
−8.1 mmHg
liraglutide
Systolic BP change
−2.6 mmHg
placebo
Source sentences
Summary
Liraglutide-treated subjects also had a significant improvement in SSPG concentration (-3.2 vs. 0.2 mmol/L; P<0.001) and significantly (P≤0.04) greater lowering of systolic blood pressure (-8.1 vs. -2.6 mmHg), fasting glucose (-0.5 vs. 0 mmol/L), and triglyceride (-0.4 vs. -0.1 mmol/L) concentration.
1 context sentence(design, population, supporting numbers)
Summary · context
We randomized 68 older individuals (mean age, 58±8 years) with overweight/obesity and prediabetes to this double-blind study of liraglutide 1.8 mg versus placebo for 14 weeks.
Report a problemFND-2383568404
05HumanRandomized controlled trialEfficacy outcome
In older adults with overweight or obesity and prediabetes, liraglutide lowered fasting glucose more than placebo (-0.5 vs 0 mmol/L).
In plain wordsIn older adults with overweight and prediabetes, liraglutide lowered fasting glucose more than placebo.
Peptide
Liraglutide
Outcome
DecreaseFasting glucose change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · 14 weeksAs given in this study (human).
Measurements
Fasting glucose change
−0.5 mmol/L
liraglutide
Fasting glucose change
0 mmol/L
placebo
Source sentences
Summary
Liraglutide-treated subjects also had a significant improvement in SSPG concentration (-3.2 vs. 0.2 mmol/L; P<0.001) and significantly (P≤0.04) greater lowering of systolic blood pressure (-8.1 vs. -2.6 mmHg), fasting glucose (-0.5 vs. 0 mmol/L), and triglyceride (-0.4 vs. -0.1 mmol/L) concentration.
1 context sentence(design, population, supporting numbers)
Summary · context
We randomized 68 older individuals (mean age, 58±8 years) with overweight/obesity and prediabetes to this double-blind study of liraglutide 1.8 mg versus placebo for 14 weeks.
Report a problemFND-2383568405
06HumanRandomized controlled trialEfficacy outcome
In older adults with overweight or obesity and prediabetes, liraglutide lowered triglyceride concentration more than placebo (-0.4 vs -0.1 mmol/L).
In plain wordsIn older adults with overweight and prediabetes, liraglutide lowered triglycerides more than placebo.
Peptide
Liraglutide
Outcome
DecreaseTriglyceride change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
1.8 mg · 14 weeksAs given in this study (human).
Measurements
Triglyceride change
−0.4 mmol/L
liraglutide
Triglyceride change
−0.1 mmol/L
placebo
Source sentences
Summary
Liraglutide-treated subjects also had a significant improvement in SSPG concentration (-3.2 vs. 0.2 mmol/L; P<0.001) and significantly (P≤0.04) greater lowering of systolic blood pressure (-8.1 vs. -2.6 mmHg), fasting glucose (-0.5 vs. 0 mmol/L), and triglyceride (-0.4 vs. -0.1 mmol/L) concentration.
1 context sentence(design, population, supporting numbers)
Summary · context
We randomized 68 older individuals (mean age, 58±8 years) with overweight/obesity and prediabetes to this double-blind study of liraglutide 1.8 mg versus placebo for 14 weeks.
Report a problemFND-2383568406
07HumanRandomized controlled trialEfficacy outcome
In older adults with overweight or obesity and prediabetes, inflammatory markers did not differ between liraglutide and placebo.
In plain wordsIn older adults with overweight and prediabetes, inflammatory markers were no different on liraglutide than on placebo.
Peptide
Liraglutide
Outcome
No significant changeInflammatory markers
Study
n: not reported in source
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
1.8 mg · 14 weeksAs given in this study (human).
Source sentences
Summary
Inflammatory markers did not differ between the two groups
1 context sentence(design, population, supporting numbers)
Summary · context
We randomized 68 older individuals (mean age, 58±8 years) with overweight/obesity and prediabetes to this double-blind study of liraglutide 1.8 mg versus placebo for 14 weeks.
Report a problemFND-2383568407
08HumanRandomized controlled trialSafety outcome
In older adults with overweight or obesity and prediabetes, pulse rose with liraglutide (6.4 bpm) and fell slightly with placebo (-0.9 bpm).
In plain wordsIn older adults with overweight and prediabetes, pulse rose on liraglutide but fell slightly on placebo.
Peptide
Liraglutide
Outcome
IncreasePulse change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
1.8 mg · 14 weeksAs given in this study (human).
Measurements
Pulse change
6.4 bpm
liraglutide
Pulse change
−0.9 bpm
placebo
Source sentences
Summary
but pulse increased after liraglutide treatment (6.4 vs. -0.9 bpm; P=0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We randomized 68 older individuals (mean age, 58±8 years) with overweight/obesity and prediabetes to this double-blind study of liraglutide 1.8 mg versus placebo for 14 weeks.
Report a problemFND-2383568408

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT02930265

Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy

Chinese PLA General Hospitaln = 400Sept 2016 to est. Mar 2018

Ischemic Cardiomyopathy

Trial page ClinicalTrials.govUpdated 12 Oct 2016

CompletedPhase 3Results postedNCT01784965

Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.

Stanford Universityn = 69Dec 2009 to Dec 2012

Pre-diabetes · Older Adults

Trial page ClinicalTrials.govUpdated 21 Apr 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.